Antigens, Neoplasm
"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Descriptor ID |
D000951
|
MeSH Number(s) |
D23.050.285
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 | 1996 | 1 | 0 | 1 | 1997 | 0 | 6 | 6 | 1998 | 2 | 3 | 5 | 1999 | 1 | 2 | 3 | 2000 | 3 | 1 | 4 | 2001 | 1 | 7 | 8 | 2002 | 3 | 5 | 8 | 2003 | 2 | 2 | 4 | 2004 | 1 | 0 | 1 | 2005 | 4 | 3 | 7 | 2006 | 4 | 2 | 6 | 2007 | 5 | 2 | 7 | 2008 | 6 | 4 | 10 | 2009 | 3 | 2 | 5 | 2010 | 5 | 1 | 6 | 2011 | 2 | 3 | 5 | 2012 | 2 | 2 | 4 | 2013 | 7 | 7 | 14 | 2014 | 8 | 3 | 11 | 2015 | 2 | 2 | 4 | 2016 | 13 | 3 | 16 | 2017 | 6 | 5 | 11 | 2018 | 7 | 6 | 13 | 2019 | 9 | 2 | 11 | 2020 | 9 | 3 | 12 | 2021 | 7 | 3 | 10 | 2022 | 1 | 4 | 5 | 2023 | 2 | 6 | 8 | 2024 | 3 | 7 | 10 | 2025 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
Cho BC, Johnson M, Bar J, Schaefer E, Yoh K, Zer A, Moskovitz M, Lee SH, Moreno V, de Miguel M, Okuma Y, Kim JH, Lee CH, Peguero J, Ansell P, Biesdorf C, Saab R, Freise KJ, Ramies D, Jeng EE, Camidge DR. A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer. Lung Cancer. 2025 Apr; 202:108492.
-
Leko V, Groh E, Levi ST, Copeland AR, White BS, Gasmi B, Li Y, Hill V, Gurusamy D, Levin N, Kim SP, Sindiri S, Gartner JJ, Prickett TD, Parkhust M, Lowery FJ, Goff SL, Rosenberg SA, Robbins P. Utilization of primary tumor samples for cancer neoantigen discovery. J Immunother Cancer. 2025 Jan 11; 13(1).
-
Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, L?wer M, M?ller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, L?rks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kr?ner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, T?reci ?, Camidge DR. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025 Jan; 31(1):152-164.
-
Borgers JSW, Lenkala D, Kohler V, Jackson EK, Linssen MD, Hymson S, McCarthy B, O'Reilly Cosgrove E, Balogh KN, Esaulova E, Starr K, Ware Y, Klobuch S, Sciuto T, Chen X, Mahimkar G, Sheen JHF, Ramesh S, Wilgenhof S, van Thienen JV, Scheiner KC, Jedema I, Rooney M, Dong JZ, Srouji JR, Juneja VR, Arieta CM, Nuijen B, Gottstein C, Finney OC, Manson K, Nijenhuis CM, Gaynor RB, DeMario M, Haanen JB, van Buuren MM. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med. 2025 Mar; 31(3):881-893.
-
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors. Cancer Genomics Proteomics. 2025 Jan-Feb; 22(1):1-12.
-
Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025 Jan 14; 58(1):232-246.e6.
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24).
-
Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024 Oct 10; 42(29):3421-3429.
-
Miller E, Biesemier A, Coomes DM, Raghavan SS. PRAME Expression in Merkel Cell Carcinoma. Am J Surg Pathol. 2024 Oct 01; 48(10):1270-1276.
-
Parkhurst M, Goff SL, Lowery FJ, Beyer RK, Halas H, Robbins PF, Prickett TD, Gartner JJ, Sindiri S, Krishna S, Zacharakis N, Ngo L, Ray S, Bera A, Shepherd R, Levin N, Kim SP, Copeland A, Nah S, Levi S, Parikh N, Kwong MLM, Klemen ND, Yang JC, Rosenberg SA. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat Med. 2024 Sep; 30(9):2586-2595.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|